|
1
|
European Network of Cancer Registries.
Eurocim version 4.0, . European incidence database. V2.3, 730
entity dictionary (2001). Lyon: 2001
|
|
2
|
Katz DL, Zheng T, Holford TR and Flannery
J: Time trends in the incidence of renal carcinoma: Analysis of
Connecticut tumor registry data, 1935–1989. Int J Cancer. 58:57–63.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Mulder PH, van Herpen CM and Mulders
PA: Current treatment of renal cell carcinoma. Ann Oncol. 15 Suppl
4:iv319–iv328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lindblad P: Epidemiology of renal cell
carcinoma. Scand J Surg. 93:88–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seizinger BR, Rouleau GA, Ozelius LJ, Lane
AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D,
Majoor-Krakauer D, et al: Von Hippel-Lindau disease maps to the
region of chromosome 3 associated with renal cell carcinoma.
Nature. 332:268–269. 1988. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nickerson ML, Jaeger E, Shi Y, Durocher
JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko
V, et al: Improved identification of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin Cancer Res.
14:4726–4734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yagoda A, Petrylak D and Thompson S:
Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin
North Am. 20:303–321. 1993.PubMed/NCBI
|
|
8
|
Gore ME, Griffin CL, Hancock B, Patel PM,
Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, et
al: Interferon alfa-2a versus combination therapy with interferon
alfa-2a, interleukin-2 and fluorouracil in patients with untreated
metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An
open-label randomised trial. Lancet. 375:641–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patard JJ, Rioux-Leclercq N and Fergelot
P: Understanding the importance of smart drugs in renal cell
carcinoma. Eur Urol. 49:633–643. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 375:1803–1813. 2015. View Article : Google Scholar
|
|
11
|
Rahat MA and Shakya J: Parallel aspects of
the microenvironment in cancer and autoimmune disease. Mediators
Inflamm. 2016:43751202016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moon SY and Zheng Y: Rho GTPase-activation
proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho HJ, Kim IK, Park SM, Baek KE, Nam IK,
Park SH, Ryu KJ, Choi J, Ryu J, Hong SC, et al: VEGF-C mediates
RHoGDI2-induced gastric cancer cell metastasis and cisplatin
resistance. Int J Cancer. 135:1553–1563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Theodorescu D, Sapinoso LM, Conaway MR,
Oxford G, Hampton GM and Frierson HF Jr: Reduced expression of
metastasis suppressor RHoGDI2 is associated with decreased survival
for patients with bladder cancer. Clin Cancer Res. 10:3800–3806.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gildea JJ, Seraj MJ, Oxford G, Harding MA,
Hampton GM, Moskaluk CA, Frierson HF, Conaway MR and Theodorescu D:
RHoGDI2 is an invasion and metastasis suppressor gene in human
cancer. Cancer Res. 62:6418–6423. 2002.PubMed/NCBI
|
|
16
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stenzl A and deKernion JB: Pathology,
biology, and clinical staging of renal cell carcinoma. Semin Oncol.
16 1 Suppl 1:S3–S11. 1989.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta c(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
R core team (2013. r: A language and
environment for statistical computing, . r foundation for
statistical computing. vienna, austria: http://www.R-project.org/
|
|
21
|
Schmidt A and Hall A: Guanine nucleotide
exchange factors for RHo GTPases: Turning on the switch. Genes Dev.
16:1587–1609. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fukumoto Y, Kaibuchi K, Hori Y, Fujioka H,
Araki S, Ueda T, Kikuchi A and Takai Y: Molecular cloning and
characterization of a novel type of regulatory protein (GDI) for
the RHo proteins, ras p21-like small GTP-binding proteins.
Oncogene. 5:1321–1328. 1990.PubMed/NCBI
|
|
23
|
Tapper J, Kettunen E, El-Rifai W, Seppälä
M, Andersson LC and Knuutila S: Changes in gene expression during
progression of ovarian carcinoma. Cancer Genet Cytogenet. 128:1–6.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho HJ, Baek KE, Park SM, Kim IK, Choi YL,
Cho HJ, Nam IK, Hwang EM, Park JY, Han JY, et al: RhoGDI2
expression is associated with tumor growth and malignant
progression of gastric cancer. Clin Cancer Res. 15:2612–2619. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y and Zhang B: D4-GDI, a RHo GTPase
regulator, promotes breast cancer cell invasiveness. Cancer Res.
66:5592–5598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by 02-regulated prolyl
hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Patel PH, Chadalavada RS, Chaganti RS and
Motzer RJ: Targeting von Hippel-Lindau pathway in renal cell
carcinoma. Clin Cancer Res. 12:7215–7220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sabo E, Boltenko A, Sova Y, Stein A,
Kleinhaus S and Resnick MB: Microscopic analysis and significance
of vascular architectural complexity in renal cell carcinoma. Clin
Cancer Res. 7:533–537. 2001.PubMed/NCBI
|
|
29
|
Qian CN, Huang D, Wondergem B and Teh BT:
Complexity of tumor vasculature in clear cell renal cell carcinoma.
Cancer. 115 10 Suppl:S2282–S2289. 2009. View Article : Google Scholar
|
|
30
|
Rini BI and Small EJ: Biology and clinical
development of vascular endothelial growth factor-targeted therapy
in renal cell carcinoma. J Clin Oncol. 23:1028–1043. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rini BI, Michaelson MD, Rosenberg JE,
Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon
CS, DePrimo SE, et al: Antitumor activity and biomarker analysis of
sunitinib in patients with bevacizumab-refractory metastatic renal
cell carcinoma. J Clin Oncol. 26:3743–3748. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chow LQ and Eckhardt SG: Sunitinib: From
rational design to clinical efficacy. J Clin Oncol. 25:884–896.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Escudier B, Bellmunt J, Négrier S, Bajetta
E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S and
Sneller V: Phase III trial of bevacizumab plus interferon alfa-2a
in patients with metastatic renal cell carcinoma (AVOREN): Final
analysis of overall survival. J Clin Oncol. 28:2144–2150. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cao Y, Linden P, Farnebo J, Cao R,
Eriksson A, Kumar V, Qi JH, Claesson-Welsh L and Alitalo K:
Vascular endothelial growth factor c induces angiogenesis in vivo.
Proc Natl Acad Sci USA. 95:pp. 14389–14394. 1998, View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dias S, Choy M, Alitalo K and Rafii S:
Vascular endothelial growth factor (VEGF)-c signaling through Flt-4
(VEGFR-3) mediates leukemic cell proliferation, survival, and
resistance to chemotherapy. Blood. 99:2179–2184. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scherle P, Behrens T and Staudt LM:
Ly-GDI, a GDP-dissociation inhibitor of the RHoA GTP-binding
protein, is expressed preferentially in lymphocytes. Proc Natl Acad
Sci USA. 90:pp. 7568–7572. 1993, View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bromwich EJ, McArdle PA, Canna K, McMillan
DC, McNicol AM, Brown M and Aitchison M: The relationship between
t-lymphocyte infiltration, stage, tumour grade and survival in
patients undergoing curative surgery for renal cell cancer. Br J
Cancer. 89:1906–1908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang QJ, Hanada KI, Robbins PF, Li YF and
Yang JC: Distinctive features of the differentiated phenotype and
infiltration of tumor-reactive lymphocytes in clear cell renal cell
carcinoma. Cancer Res. 72:6119–6129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mehta P, Wavreille AS, Justiniano SE,
Marsh RL, Yu J, Burry RW, Jarjoura D, Eubank T, Caligiuri MA,
Butchar JP and Tridandapani S: LyGDI, a novel ship-interacting
protein, is a negative regulator of FcγR-mediated phagocytosis.
PLoS One. 6:e211752011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Groysman M, Hornstein I, Alcover A and
Katzav S: Vav1 and Ly-GDI two regulators of RHo GTPases, function
cooperatively as signal transducers in T cell antigen
receptor-induced pathways. J Biol Chem. 277:50121–50130. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garcia-Cozar FJ, Okamura H, Aramburu JF,
Shaw KT, Pelletier L, Showalter R, Villafranca E and Rao A:
Two-site interaction of nuclear factor of activated t cells with
activated calcineurin. J Biol Chem. 273:23877–23883. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
VON Klot CA, Merseburger AS and Kuczyk MA:
Novel therapeutic options for second-line therapy in metastatic
renal cell carcinoma. Mol Clin Oncol. 4:903–908. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Uhlen M, Oksvold P, Fagerberg L, Lundberg
E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S,
et al: Towards a knowledge-based human protein atlas. Nat
Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Image (43)/ARHGDIB/data available from
v16.1, . proteinatlas.org. https://www.proteinatlas.org/ENSG00000111348-ARHGDIB/cancer/tissue/renal+cancer#img
|
|
47
|
Balch CM, Riley LB, Bae YJ, Salmeron MA,
Platsoucas CD, von Eschenbach A and Itoh K: Patterns of human
tumor-infiltrating lymphocytes in 120 human cancers. Arch. Surg.
125:200–205. 1990.
|
